David A. Scheinberg
SCIENTIFIC ADVISORY BOARD
Pharmaceutical Sciences
Sellas Life Sciences Group
Canada
Biography
David A. Scheinberg, MD, PhD, is Chair of the Center for Experimental Therapeutics and the Vincent Astor Chair at Memorial Sloan Kettering Cancer Center (MSKCC), where he treats patients with leukemia. Dr. Scheinberg also serves as Chair of the Molecular Pharmacology Program at the Sloan Kettering Institute. He is a professor of medicine and of pharmacology at Weill Cornell Medical College and a founder and director of the Therapeutics Discovery Institute, a joint effort of Weill Cornell, the Rockefeller University, and MSKCC. Dr. Scheinberg’s research is focused on discovering and developing novel, specific immunotherapeutic agents and to understand their mechanisms of action as well as the mechanisms of resistance to them. Eight different therapeutic agents developed in Dr. Scheinberg’s laboratory have reached human clinical trials. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg received his bachelor’s degree from Cornell University and his MD and PhD in pharmacology and experimental therapeutics from the Johns Hopkins University School of Medicine. David A. Scheinberg, MD, PhD, is Chair of the Center for Experimental Therapeutics and the Vincent Astor Chair at Memorial Sloan Kettering Cancer Center (MSKCC), where he treats patients with leukemia. Dr. Scheinberg also serves as Chair of the Molecular Pharmacology Program at the Sloan Kettering Institute. He is a professor of medicine and of pharmacology at Weill Cornell Medical College and a founder and director of the Therapeutics Discovery Institute, a joint effort of Weill Cornell, the Rockefeller University, and MSKCC. Dr. Scheinberg’s research is focused on discovering and developing novel, specific immunotherapeutic agents and to understand their mechanisms of action as well as the mechanisms of resistance to them. Eight different therapeutic agents developed in Dr. Scheinberg’s laboratory have reached human clinical trials. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg received his bachelor’s degree from Cornell University and his MD and PhD in pharmacology and experimental therapeutics from the Johns Hopkins University School of Medicine.
Research Interest
Pharmaceutical Sciences